GIBSON DUNN

Gibson Dunn Advises Mentari Therapeutics on Merger With InMed Pharmaceuticals and Concurrent $290 Million Private Placement

Firm News | May 21, 2026

Gibson Dunn is advising Mentari Therapeutics, Inc. on its merger with InMed Pharmaceuticals, Inc. and concurrent $290 million private placement.

The Gibson Dunn corporate team includes partners Ryan Murr and Branden Berns and associate Evan Shepherd.

Related People

Ryan A. Murr

Branden C. Berns

Evan Shepherd

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**